ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM
Abstract Number: 0082
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
9:00AM-11:00AM
Abstract Number: 0070
Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis
9:00AM-11:00AM
Abstract Number: 0069
All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome
9:00AM-11:00AM
Abstract Number: 0068
Anti-TNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity
9:00AM-11:00AM
Abstract Number: 0079
CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles
9:00AM-11:00AM
Abstract Number: 0076
Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
9:00AM-11:00AM
Abstract Number: 0077
Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome
9:00AM-11:00AM
Abstract Number: 0078
Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
9:00AM-11:00AM
Abstract Number: 0072
Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
9:00AM-11:00AM
Abstract Number: 0067
Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples
9:00AM-11:00AM
Abstract Number: 0074
Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects
9:00AM-11:00AM
Abstract Number: 0084
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
9:00AM-11:00AM
Abstract Number: 0083
Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses
9:00AM-11:00AM
Abstract Number: 0085
Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis
9:00AM-11:00AM
Abstract Number: 0094
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
9:00AM-11:00AM
Abstract Number: 0087
Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients
9:00AM-11:00AM
Abstract Number: 0091
Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity
9:00AM-11:00AM
Abstract Number: 0095
Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE
9:00AM-11:00AM
Abstract Number: 0066
Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease
9:00AM-11:00AM
Abstract Number: 0092
Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
9:00AM-11:00AM
Abstract Number: 0086
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
9:00AM-11:00AM
Abstract Number: 0073
PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
9:00AM-11:00AM
Abstract Number: 0080
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
9:00AM-11:00AM
Abstract Number: 0089
Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 0075
Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)
9:00AM-11:00AM
Abstract Number: 0081
RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
9:00AM-11:00AM
Abstract Number: 0090
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 0071
Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease
9:00AM-11:00AM
Abstract Number: 0093
Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 0088
SLAMF4 Orchestrates the Pathological Cytotoxic Response of CD4+ T Cells in Rheumatoid Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology